PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
企業コードPMCB
会社名PharmaCyte Biotech Inc
上場日Sep 11, 2003
最高経営責任者「CEO」Silverman (Joshua N)
従業員数2
証券種類Ordinary Share
決算期末Sep 11
本社所在地3960 Howard Hughes Parkway, Suite 500
都市LAS VEGAS
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号89169
電話番号19175952850
ウェブサイトhttps://pharmacyte.com/
企業コードPMCB
上場日Sep 11, 2003
最高経営責任者「CEO」Silverman (Joshua N)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし